Rosiglitazone and Its Effects on Breast Cancer Metastasis
Author Information
Author(s): Magenta Gabriela, Borenstein Ximena, Rolando Romina, Jasnis María Adela
Primary Institution: Institute of Oncology AH Roffo, Buenos Aires, Argentina
Hypothesis
Does rosiglitazone induce antitumor effects on the murine mammary tumor cell line LMM3?
Conclusion
Rosiglitazone significantly decreased lung metastasis in mice without affecting primary tumor growth.
Supporting Evidence
- Rosiglitazone reduced the number of lung metastases in treated mice.
- Primary tumor growth was not affected by rosiglitazone treatment.
- Cell adhesion and migration were significantly inhibited by rosiglitazone.
Takeaway
Rosiglitazone can help stop cancer cells from spreading to the lungs, but it doesn't shrink the main tumor.
Methodology
The study used in vitro and in vivo experiments to assess the effects of rosiglitazone on tumor cell viability, adhesion, migration, and metastasis.
Potential Biases
Potential bias due to the use of a single tumor cell line and specific experimental conditions.
Limitations
The study did not explore the long-term effects of rosiglitazone or its impact on primary tumor growth.
Participant Demographics
Female inbred BALB/c mice aged 6-8 weeks were used for in vivo experiments.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website